OncoMatch/Clinical Trials/NCT04716452
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Is NCT04716452 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Ceramide NanoLiposome (Ceraxa) for acute myeloid leukemia, in relapse.
Treatment: Ceramide NanoLiposome (Ceraxa) — The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Kidney function
Creatinine clearance > 60 mL/min
Liver function
Total bilirubin ≤ 1.5 × ULN or < 3 x ULN for patients with Gilbert-Meulengracht Syndrome; AST and ALT ≤ 3 × ULN if not attributed to leukemia, or ≤ 5 x ULN if attributed to leukemia
Adequate organ function as evidenced by the following laboratory findings: * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) or < 3 x ULN for patients with Gilbert-Meulengracht Syndrome * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN if not attributed to leukemia, or ≤ 5 x ULN if attributed to leukemia * Creatinine clearance > 60 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Virginia Cancer Center · Charlottesville, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04716452 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages